BioStock: Arcede Pharma prepares for clinical studies

The second Advent candle had just been lit when Lund-based Arcede Pharma released its Q2 report for the fiscal year 2022. The company is busy working on the the final parts of the toxicology program, whilst at the same time preparing the drug candidate RCD405 for clinical studies. BioStock talked to Arcede Pharma’s CEO Mia Lundblad about her view of the past quarter and what is next for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/12/arcede-pharma-prepares-for-clinical-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se